Bausch + Lomb falls 3% as investors brace for April 29 earnings
Bausch + Lomb shares slid as investors positioned ahead of the company’s Q1 2026 earnings report on April 29, 2026. The stock has also remained sensitive to lingering uncertainty around the enVista intraocular lens recall timeline and its potential financial impact.
1. What’s moving the stock today
Bausch + Lomb (BLCO) traded lower Tuesday as the market looked ahead to the company’s next catalyst: first-quarter 2026 results scheduled for April 29, 2026. With the report a little over a week away, trading action suggests investors are de-risking into the print rather than reacting to a single new headline.
2. Recall uncertainty remains an overhang
BLCO sentiment has been shaped by ongoing questions tied to the enVista intraocular lens recall, including how long remediation takes and how it affects premium IOL momentum. Analyst commentary tied past rating and target changes to recall-related uncertainty and the difficulty of pinning down a clean timeline for normalization.
3. Near-term calendar and what to watch next
The key near-term event is the April 29 earnings release and conference call, where investors will focus on any update to 2026 revenue and profitability expectations and commentary on surgical/vision care demand trends. Any change in guidance language, or updates on premium IOL recovery and product rollout cadence, could quickly reset expectations for the stock.